Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin
- 1 June 1987
- journal article
- review article
- Published by Wiley in European Journal of Haematology
- Vol. 38 (S47) , 7-20
- https://doi.org/10.1111/j.1600-0609.1987.tb00018.x
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Chemosensitizers counteracting acquired resistance to anthracyclines and vinca alkaloidsin vivo. A new treatment principleCancer Treatment Reviews, 1984
- The influence of aclacinomycin a on the immune response and on experimental immune disordersInternational Journal of Immunopharmacology, 1984
- Alteration of plasma membrane of drug-resistant tumor cells: 230-Kilodalton protein identified by monoclonal antibodyBiochemical and Biophysical Research Communications, 1983
- Mutagenicity of eight anthracycline derivatives in five strains of Salmonella typhimuriumEuropean Journal of Cancer and Clinical Oncology, 1983
- Development and cross-resistance characteristics of a subline of P388 leukemia resistant to 4′-(9-acridinylamino)-methanesulfon-m-anisidideEuropean Journal of Cancer and Clinical Oncology, 1982
- Anthracycline-induced histamine release from rat mast cellsInflammation Research, 1982
- Membrane transport of anthracyclinesPharmacology & Therapeutics, 1982
- Antitumor efficacies of aclacinomycin A by oral administration.Journal of Pharmacobio-Dynamics, 1980
- Deoxyribonucleic acid binding studies on several new anthracycline antitumor antibiotics. Sequence preference and structure-activity relationships of marcellomycin and its analogs as compared to adriamycinBiochemistry, 1979